Palmetto Chooses Innovation Over the Status Quo

If you don’t know where you’re going, any road will get you there

– The Cheshire Cat, Alice in Wonderland

Even our most rudderless acquaintances would surely take offense at the idea that they act without considering the repercussions of their actions. Why then do we sometimes observe carefully implemented plans that yield outcomes which can neither be described as desirable nor surprising? Was taking action an end in and of itself?

recently-published Brookings white paper draws attention to an example of this in Medicare’s history of payment for advanced medical imaging (CT, MRI, nuclear scans) over the last 20 years. In that time, wide payment and practice swings occurred based on factors largely removed from clinical value, effectiveness, or costs. The Brookings paper’s authors find that “there is no evidence that the results [of the driving policy shifts] were anticipated or planned.”

So what shifted? First, in 2008-2010, after years of physicians increasingly referring patients to non-hospital imaging centers for advanced imaging, Medicare payments began prioritizing hospital outpatient imaging over non-hospital centers. This resulted in a 40% decline in advanced imaging studies being ordered for Medicare patients. Second, payment amounts have continued to diverge across sites of service, with the prioritized hospital imaging being paid at a significantly higher rate, even though the clinical services offered are nearly identical.

Today, advanced medical imaging is characterized by rapid technological advances, such as the use of AI, providing benefits to patients, providers, and payers. But to move from breakthrough to standard of care, even innovations proven to deliver improved clinical outcomes require agile consideration from major healthcare stakeholders to enable clinicians to evolve from the status quo. Palmetto GBA, who handles healthcare claims for Medicare beneficiaries in seven southeastern US states, is one of these leading stakeholders.

Palmetto has led efforts to ensure coverage for innovative healthcare services, such as the AI-driven HeartFlow FFRCT Analysis for patients with coronary artery disease. Importantly and unique among its peers, Palmetto has also adopted site neutrality when paying claims for the HeartFlow Analysis, enabling similar reimbursement amounts in both hospital and non-hospital settings, in line with the recommendations of the Brookings white paper.

Through Palmetto’s work, physicians can use HeartFlow to assess a patient’s heart health non-invasively in any clinical setting without worrying about financial imbalances. Prior to site neutrality, CMS reimbursement sometimes fell by 90% or more if the service was delivered at a non-hospital imaging center, making it difficult to serve Medicare beneficiaries in these sites.

By establishing coverage and payment site neutrality, Palmetto’s decision to expand access to HeartFlow for millions of Medicare beneficiaries has a clear goal: clinicians can use an innovative pathway to improve patient outcomes, reduce unnecessary procedures, ensure efficient use of resources, and enable a better patient experience as they provide care in convenient locations.

In our interconnected healthcare environment, almost every decision can either support or suppress innovation. Leaders like Palmetto can either take purposeful steps to enable clinicians to choose new innovative pathways, or they can simply remain static and enable the status quo.

To this thought, the Brookings white paper authors write “Surely, we can do better.” And they are correct. As Medicare seeks to enable value-based medicine across the U.S., we must know where we are going if we are to have any chance of choosing the right road to get there.

— A perspective from HeartFlow Chief Medical Officer, Campbell Rogers, MD
Bio | LinkedIn

Contact Us

*Required fields

Request the HeartFlow Analysis Near You

If you would like to request to have the HeartFlow Analysis available at a location near you, please submit your information below with details of the institution. We will share this information with the institution, but it will not guarantee HeartFlow will become available.

*Required fields

残念ながら、GDPR 規制により、この Web フォームを通じて求人への応募やキャリアに関する問い合わせを受け付けることはできません。弊社を通じてお申込みください 採用ページ. ご関心をお寄せいただきありがとうございます!

オンライン提出フォームから研究助成金を申請してください。

HeartFlow FFRCT 分析は、有資格の臨床医による臨床的に安定した症状のある冠状動脈疾患患者への使用を目的とした個別化された心臓検査です。 HeartFlow Analysis によって提供される情報は、資格のある臨床医が患者の病歴、症状、その他の診断検査、および臨床医の専門的判断と組み合わせて使用​​することを目的としています。

ハートフロー分析に関する追加の適応情報については、次のサイトをご覧ください。www.heartflow.com/indications.

さらに質問がある場合は、このメッセージを閉じてフォームに記入するか、サポート チームにお電話ください。: 877.478.3569.

The HeartFlow FFRCT Analysis is a personalized cardiac test indicated for use in clinically stable symptomatic patients with coronary artery disease by qualified clinicians. The information provided by the HeartFlow Analysis is intended to be used by qualified clinicians in conjunction with the patient’s history, symptoms, and other diagnostic tests, as well as the clinician’s professional judgement.

For additional indication information about the HeartFlow Analysis, please visit www.heartflow.com/indications.

If you have additional questions, close out of this message to complete our form or call our support team: 877.478.3569.

Please use our online submission form on the Clinical Research Page to apply for research grants.

Thank you for your interest!

Unfortunately, we cannot take job applications or career inquiries through this web form due to GDPR regulations. Please apply through our Careers Page. Thank you for your interest!

Campbell Rogers, M.D., F.A.C.C.

Executive Vice President and Chief Medical Officer

Campbell brings a wealth of experience to HeartFlow, where he serves as the Chief Medical Officer. Prior to joining HeartFlow, he was the Chief Scientific Officer and Global Head of Research and Development at Cordis Corporation, Johnson & Johnson, where he was responsible for leading investments and research in cardiovascular devices. Prior to Cordis, he was Associate Professor of Medicine at Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, and Director of the Cardiac Catheterization and Experimental Cardiovascular Interventional Laboratories at Brigham and Women’s Hospital. He served as Principal Investigator for numerous interventional cardiology device, diagnostic, and pharmacology trials, is the author of numerous journal articles, chapters, and books in the area of coronary artery and other cardiovascular diseases, and was the recipient of research grant awards from the NIH and AHA.

He received his A.B. from Harvard College and his M.D. from Harvard Medical School.